Clinical Trial Update: A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes ongoing Phase 1/2 studies evaluating Ivonescimab in combination with Dato-DXd or Osimertinib for non-small cell lung cancer, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Ivonescimab (AK112/SMT112)
• Osimertinib (Tagrisso) (osimertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING